DexCom, Inc. $DXCM Shares Sold by Howard Capital Management Inc.

Howard Capital Management Inc. reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 5.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,934 shares of the medical device company’s stock after selling 534 shares during the period. Howard Capital Management Inc.’s holdings in DexCom were worth $780,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in DXCM. Vanguard Group Inc. raised its stake in DexCom by 2.0% in the 1st quarter. Vanguard Group Inc. now owns 47,455,899 shares of the medical device company’s stock worth $3,240,763,000 after acquiring an additional 925,882 shares during the last quarter. Jennison Associates LLC increased its holdings in shares of DexCom by 37.7% in the first quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company’s stock valued at $718,632,000 after purchasing an additional 2,879,489 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of DexCom by 22.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock worth $691,336,000 after purchasing an additional 1,868,241 shares during the last quarter. Nuveen LLC acquired a new stake in shares of DexCom during the first quarter worth about $554,893,000. Finally, Raymond James Financial Inc. boosted its position in DexCom by 21.8% in the first quarter. Raymond James Financial Inc. now owns 3,355,057 shares of the medical device company’s stock valued at $229,117,000 after buying an additional 601,088 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Kyle Malady sold 667 shares of DexCom stock in a transaction on Friday, September 5th. The shares were sold at an average price of $80.86, for a total value of $53,933.62. Following the sale, the director owned 22,667 shares of the company’s stock, valued at approximately $1,832,853.62. This trade represents a 2.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 1,466 shares of the business’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total transaction of $117,280.00. Following the completion of the sale, the executive vice president directly owned 105,223 shares of the company’s stock, valued at approximately $8,417,840. The trade was a 1.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 5,383 shares of company stock valued at $434,274 in the last three months. 0.32% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on DXCM. Raymond James Financial raised their price target on shares of DexCom from $99.00 to $102.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 31st. Cowen restated a “buy” rating on shares of DexCom in a research report on Friday, October 24th. Citigroup lowered their price target on shares of DexCom from $105.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday, October 7th. Argus initiated coverage on DexCom in a research note on Thursday, August 21st. They set a “buy” rating and a $100.00 price objective for the company. Finally, Piper Sandler set a $100.00 target price on DexCom and gave the stock an “overweight” rating in a research note on Tuesday, October 21st. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus price target of $97.19.

DexCom Trading Down 1.5%

Shares of DexCom stock opened at $68.18 on Thursday. The firm has a 50-day simple moving average of $71.67 and a two-hundred day simple moving average of $78.03. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25. The company has a market cap of $26.74 billion, a P/E ratio of 47.35, a price-to-earnings-growth ratio of 1.45 and a beta of 1.47.

DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.03. The firm had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The company’s quarterly revenue was up 15.2% on a year-over-year basis. During the same period last year, the firm earned $0.43 EPS. As a group, equities analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.